ArticleNPJ breast cancer2021
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
Open access · goldAbstract read
In one paragraph
Article in NPJ breast cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Overexpression ofTranslational cancer research · 2025Article
- Rhodosporidium toruloides-a new surrogate model to study rapamycin induced effects on human aging and cancer.Cellular and molecular life sciences : CMLS · 2025Article
- The SGK3/GSK3β/β-catenin signaling promotes breast cancer stemness and confers resistance to alpelisib therapy.International journal of biological sciences · 2025Article
- Expression of gamma-aminobutyric acid type A receptor subunit π and minichromosome maintenance-3 in breast cancer patients treated with neoadjuvant chemotherapy: a target molecule or a proliferation marker?Revista da Associacao Medica Brasileira (1992) · 2025Article
- Overexpression of MCM3 as a prognostic biomarker correlated with cell proliferation, cell cycle and immune regulation in hepatocellular carcinoma.Journal of Cancer · 2025Article
- Expression, potential biological behaviour and clinical significance of MCM3 in pancreatic adenocarcinoma: a comprehensive study integrating high throughput sequencing, CRISPR screening and in-house immunohistochemistry.Annals of medicine · 2024Article
- Integration of scHi-C and scRNA-seq data defines distinct 3D-regulated and biological-context dependent cell subpopulations.Nature communications · 2024Article
- Preparation of hepatocellular carcinoma mRNA vaccines based on potential tumor targets and immunophenotypes.Translational cancer research · 2024Article
- A novel upregulated hsa_circ_0032746 regulates the oncogenesis of esophageal squamous cell carcinoma by regulating miR-4270/MCM3 axis.Human genomics · 2024Article
- The prognostic and immunological role of MCM3 in pan-cancer and validation of prognosis in a clinical lower-grade glioma cohort.Frontiers in pharmacology · 2024Article
- Review
- Identification of key genes and pathways between mild-moderate and severe asthmatics via bioinformatics analysis.Scientific reports · 2022Article
- Article
- MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.NPJ breast cancer · 2021Article
- Bioinformatics Analysis RevealsComputational and mathematical methods in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 9 institutions in 3 countries.
Sanne LøkkegaardDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DK-5000, Denmark.
Daniel EliasDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DK-5000, Denmark.
Carla L AlvesDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DK-5000, Denmark.ORCID http://orcid.org/0000-0003-2266-9349
Martin V BennetzenCenter of Experimental Bioinformatics, Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, DK-5230, Denmark.
Anne-Vibeke LænkholmDepartment of Surgical Pathology, Zealand University Hospital, Roskilde, DK-4000, Denmark.
Martin BakDepartment of Pathology, Odense University Hospital, Odense, DK-5000, Denmark.ORCID http://orcid.org/0000-0002-6490-2519
Morten F GjerstorffDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DK-5000, Denmark.
Lene E JohansenDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DK-5000, Denmark.
Henriette VeverDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DK-5000, Denmark.
Christina BjerreDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, DK-2100, Copenhagen, Denmark.
Tove KirkegaardCell Death and Metabolism, Danish Cancer Society Research Center, Copenhagen, DK-2100, Denmark.
Bo NordenskjöldDepartment of Clinical and Experimental Medicine, Division of Oncology, Linköping University, Linköping, SE-58185, Sweden.
Tommy FornanderDepartment of Oncology, Karolinska University Hospital, Stockholm, SE-11883, Sweden.
Olle StålDepartment of Clinical and Experimental Medicine, Division of Oncology, Linköping University, Linköping, SE-58185, Sweden.
Linda S LindströmDepartment of Biosciences and Nutrition, Karolinska Institutet, Stockholm, SE-14183, Sweden.
Laura J EssermanDepartment of Surgery, UCSF Carol Franc Buck Breast Care Center, University of California, San Francisco, San Francisco, 94115, CA, USA.ORCID http://orcid.org/0000-0001-9202-4568
Anne E LykkesfeldtCell Death and Metabolism, Danish Cancer Society Research Center, Copenhagen, DK-2100, Denmark.
Jens S AndersenCenter of Experimental Bioinformatics, Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, DK-5230, Denmark.ORCID http://orcid.org/0000-0002-6091-140X
Rikke Leth-LarsenDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DK-5000, Denmark.
Henrik J DitzelDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DK-5000, Denmark. hditzel@health.sdu.dk.ORCID http://orcid.org/0000-0003-3927-5135
University of Southern Denmark · DKDanish Cancer Society · DKLinköping University · SECopenhagen University Hospital · DKKarolinska Institutet · SEKarolinska University Hospital · SEOdense University Hospital · DKUniversity of California, San Francisco · USZealand University Hospital · DK
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to endocrine therapy in estrogen receptor-positive (ER
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.